Healthcare Business

Biotechnology word cloud

Biotech Company FibroGen Files for IPO

FibroGen Inc. filed its S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). No terms were given for the offering, but they filed ...
Read Full Story »
research

Major Fallout Stocks After Confirmed Ebola Case in United States

Tuesday brought the very unfortunate news that a confirmed case of Ebola has arrived in the United States. With the CDC not releasing enough data on the patient, there could ...
Read Full Story »
Comfortable hospital bed

Reaction to Confirmed Ebola Case in U.S. — UPDATED

News has hit of the first confirmed Ebola case in the United States. While this news is still breaking and developing, it appears to be a case that was after ...
Read Full Story »
biotech

What Else Is Under the Hood for Catalyst Pharma?

Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX) announced positive topline results from its Phase 3 clinical trial of Firdapse for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome, or LEMS. In the ...
Read Full Story »
research

Is Ambit Biosciences Getting Enough in Its Buyout?

Ambit Biosciences Corp. (NASDAQ: AMBI) has announced that it is entering into a merger with Daiichi Sankyo. All outstanding shares of Ambit will be acquired by Daiichi Sankyo for $15 ...
Read Full Story »
biotech

Can Repros Therapeutics Shares Still More Than Double?

Repros Therapeutics Inc. (NASDAQ: RPRX) is a small cap biotech stock that is not exactly having the best year, despite big gains on Friday. With shares close to $10, its ...
Read Full Story »
Pills

Will Analysts Start Following Alimera After Its FDA Approval?

Alimera Sciences Inc. (NASDAQ: ALIM) traded up big on Monday on news that the company received U.S. Food and Drug Administration (FDA) approval for its drug Iluvien. The company stated ...
Read Full Story »
biotech

3 Likely Biotech Buyout Candidates

The pharmaceutical business is a difficult one, because patent expiration and competition are always omnipresent factors. Obviously major companies like to keep large research and development projects moving at full ...
Read Full Story »
DNA

Coherus Files for IPO: Biotech to Biosimilars

Coherus Biosciences Inc. filed an S-1 with the Securities and Exchange Commission for an initial public offering. No terms were given for the offering but it has filed to raise ...
Read Full Story »
research

Short Sellers Make Moves in Key Biotech Stocks

The short interest report is out for the September 15 settlement date, and here 247 Wall St. has decided to focus on the biotech sector. Short sellers are often active ...
Read Full Story »
Biotechnology word cloud

5 Orphan Drug Biotech Stocks to Buy With Big Upside Potential

An orphan drug is a pharmaceutical agent that has been developed specifically to treat a rare medical condition. In the United States and the European Union, it is easier to ...
Read Full Story »
research

Analyst Now Sees 75% Upside in Sarepta

Sarepta Therapeutics Inc. (NASDAQ: SRPT) has an incredible analyst call with a new Outperform rating issued by Credit Suisse. The $36 price target is what stands out. The firm's Jeremiah ...
Read Full Story »
biotech

DBV Technologies Files for IPO, Sort Of

DBV Technologies has filed an F-1 form with the U.S. Securities and Exchange Commission (SEC) for an initial public offering (IPO). At least it is an IPO in the United ...
Read Full Story »
health care

Exagen Diagnostics Files for IPO

Exagen Diagnostics Inc. has filed its S-1 form with the U.S. Securities and Exchange Commission (SEC) for an initial public offering (IPO). No terms were given for the offering, but it ...
Read Full Story »
IPO

A First, Chiropractic IPO Filing: The Joint

The Joint Corp. filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) for an initial public offering (IPO). No terms were given for the offering, but the ...
Read Full Story »